Table 5.
Willingness to participate in HIV cure research procedures
| Very willing N (%) |
Willing N (%) |
Not sure N (%) |
Unwilling N (%) |
Very unwilling N (%) |
DNA N (%) |
DNU N (%) |
Missing N (%) |
|
| Online surveys | 29 (25) | 32 (27) | 14 (12) | 2 (2) | 4 (3) | 9 (8) | 9 (8) | 19 (16) |
| Phone/in-person interview | 34 (29) | 27 (23) | 11 (9) | 4 (3) | 5 (4) | 11 (9) | 4 (3) | 22 (19) |
| Focus group discussions | 32 (27) | 29 (25) | 10 (9) | 2 (2) | 2 (2) | 7 (6) | 8 (7) | 28 (24) |
| Blood draws | 30 (25) | 37 (31) | 5 (4) | 2 (2) | – | 9 (8) | 6 (5) | 29 (25) |
| Tissue biopsies | 22 (19) | 25 (21) | 16 (14) | 3 (3) | 3 (3) | 10 (9) | 14 (12) | 25 (21) |
| Leukapheresis/apheresis | 22 (19) | 28 (24) | 14 (12) | 6 (5) | 1 (1) | 13 (11) | 15 (13) | 19 (16) |
| Latency reversing agents | 12 (10) | 16 (14) | 23 (20) | 4 (3) | 5 (4) | 15 (13) | 23 (29) | 20 (17) |
| Gene editing | 15 (13) | 16 (14) | 25 (21) | 5 (4) | 4 (3) | 12 (10) | 21 (18) | 20 (17) |
| Autologous transplants | 18 (15) | 19 (16) | 27 (23) | 2 (2) | – | 12 (10) | 20 (17) | 20 (17) |
| Allogenic transplants | 18 (15) | 14 (12) | 22 (19) | 7 (6) | – | 12 (10) | 19 (16) | 26 (22) |
| Therapeutic vaccines | 30 (25) | 28 (23) | 13 (11) | 4 (3) | 2 (2) | 11 (9) | 13 (11) | 17 (14) |
| Treatment interruption | 19 (16) | 15 (13) | 20 (17) | 7 (6) | 4 (3) | 17 (14) | 19 (16) | 17 (14) |
| Broadly neutralising antibodies | 20 (17) | 20 (17) | 18 (15) | 8 (7) | 2 (2) | 13 (11) | 18 (15) | 19 (16) |
| Unique proteins or T cells | 19 (16) | 13 (11) | 22 (19) | 5 (4) | – | 13 (11) | 25 (21) | 21 (18) |
| New, untested treatments | 22 (19) | 27 (23) | 18 (15) | 3 (3) | 2 (2) | 13 (11) | 13 (11) | 20 (17) |
| Early safety studies | 26 (26) | 28 (24) | 19 (16) | 3 (3) | 1 (1) | 5 (4) | 12 (10) | 24 (20) |
| Efficacy studies | 24 (20) | 22 (19) | 19 (16) | 3 (3) | 1 (1) | 12 (10) | 18 (16) | 19 (16) |
DNA, does not apply; DNU, do not understand.